MétaCan
Menu
Back to cohort

Alzheimer’s Drug Combo May Lower Nursing-Home Costs

2012· article· en· W1983300744 on OpenAlexaboutno aff
Joan Arehart-Treichel

Bibliographic record

VenuePsychiatric News · 2012
Typearticle
Languageen
FieldMedicine
TopicPharmaceutical Practices and Patient Outcomes
Canadian institutionsnot available
Fundersnot available
KeywordsRivastigmineGalantamineDonepezilMemantineCholinesteraseMedicinePharmacyDementiaFormularyPsychiatryPsychologyPharmacologyFamily medicineInternal medicineDisease

Abstract

fetched live from OpenAlex

Back to table of contents Previous article Next article Clinical & Research NewsFull AccessAlzheimer's Drug Combo May Lower Nursing-Home CostsJoan Arehart-TreichelJoan Arehart-TreichelPublished Online:6 Jan 2012https://doi.org/10.1176/pn.47.1.psychnews_47_1_9-aAbstractWhen Alzheimer's patients receive a cholinesterase inhibitor such as donepezil, rivastigmine, or galantamine, it can delay the need to place them in a nursing home. And when they receive the NMDA receptor antagonist memantine plus a cholinesterase inhibitor, it can delay this placement even longer.These findings, by O.L. Lopez, M.D., a professor of neurology at the University of Pittsburgh, and colleagues have since been replicated by other researchers in North America and Europe, Lopez told Psychiatric News.Thus, if the use of memantine plus a cholinesterase inhibitor can delay nursing-home placement longer than the use of a cholinesterase inhibitor alone, can it also save money?The answer is yes, Jean Lachaine, Ph.D., an associate professor of pharmacy at the University of Montreal, and colleagues reported in the October 2011 Canadian Journal of Psychiatry.Specifically, it can save about $21,000 per patient annually (in either Canadian or American dollars) from a societal perspective, and about $31,000 per patient annually from a health care system perspective.Therefore, "the use of memantine, combined with a cholinesterase inhibitor, to treat Alzheimer's is a cost-effective alternative, compared with the use of a cholinesterase inhibitor alone," they concluded.In this analysis, they used data published by Lopez and his group as well as health care cost data published by Canadian researchers, including a large-scale Canadian epidemiologic study called the Canadian Study of Health and Aging, which is the primary reference for the costs of Alzheimer's in Canada. The costs considered included items such as medications, patient care in the community or by home health aid workers, lost productivity of caregivers due to time spent caring for patients, and nursing home costs. The costs were adjusted to 2010 values using the Canadian Consumer Price Index.Lachaine and his colleagues also found, as other researchers have, that placing Alzheimer's patients in a nursing home represents the largest cost component of managing their care.Lachaine and his colleagues either work for Lundbeck Inc. or consult to it. Lundbeck markets drugs for the treatment of Alzheimer's, as well as for other neurological or psychiatric conditions.An abstract of "Economic Evaluation of the Impact of Memantine on Time to Nursing Home Admission in the Treatment of Alzheimer Disease" is posted at http://publications.cpa-apc.org/media.php?mid=1232. ISSUES New Archived

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.652
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.105
GPT teacher head0.417
Teacher spread0.312 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venuePsychiatric NewsSame topicPharmaceutical Practices and Patient OutcomesFrench-language works237,207